Pharma pumps up lobbying spend

The pharmaceutical industry increased its lobbying presence during the first quarter of this year. Roll Call's Political MoneyLine blog notes that Pfizer, Johnson & Johnson, Bayer and Merck were at the top of the list of pharma companies whose lobbying outlays were up from the fourth quarter of 2013.

Among the increases:

Pfizer upped its lobbying efforts this quarter by almost 53%, to $3.9 million, compared to $2.1 million in the fourth quarter, while Novartis put close to $2.6 million toward lobbying in the first quarter, compared to $920,000 in the fourth quarter of last year.

J&J dialed up its efforts, to $2.1 million, up from $860,000, and Merck more than doubled its efforts, with $2 million this quarter, compared to $820,000 last quarter.

But some drugmakers dialed back their efforts: Bristol-Myers Squibb proffered $520,000 during the first quarter, down from $740,000 last quarter, while Novo Nordisk reduced its outlay to $710,000, compared to $820,000 last quarter.

You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.